Galapagos
Galapagos
0,70 %
151,00 EUR
1,05
Kurs
151,00
Hög
151,10
Förändring
0,70 %
Låg
147,60
Uppdaterad
13:50:07
Öppen
149,30
Factsheet for Galapagos
Company Profile
Description
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.
Key Stats
Website: http://www.glpg.com
Headquarter country: Belgium
Employees: 810
Market Cap (at close 22-08-2019): EUR 8B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 799,50
Forward Price/Earnings
Price/Free Cash Flow
Return on Assets -2,10 -9,80 7,10 -33,20 11,90
Return on Equity -2,60 -13,10 9,60 -41,50 17,80
Return on Invested Capital -3,00 -13,30 9,30 -41,90 17,20
Dividend


Dividend/Share:
Ex. Dividend Date:0001-01-01
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 288,84 127,09 129,52 39,56 69,37
Gross Profit -0,03 -0,09 -0,01 -0,09 -0,04
Gross Margin % -11,79% -71,93% -7,77% -227,87% -60,17%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -23,00 -110,00 58,00 -116,00 -30,00
Net income -29,00 -116,00 54,00 -118,00 33,00
Basic Earnings Per Share -0,56 -2,34 1,18 -3,32 1,10
Operating Income -0,04 -0,09 -0,01 -0,09 -0,04
Operating Margin % -15,51% -70,66% -8,87% -226,08% -51,83%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -142,00 -147,00 239,00 -115,00 -76,00
Capital Expenditures -14,00 -7,00 -5,00 -7,00 -3,00
Free Cash Flow -156,00 -154,00 235,00 -121,00 -78,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 1 328,85 1 197,65 1 007,23 374,47 213,60 176,65
Long Term Assets 110,65 88,63 76,11 68,04 56,86 110,72
Total Assets 1 439,50 1 286,27 1 083,34 442,51 270,47 287,37
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 219,91 171,70 103,79 72,41 60,36 112,56
Long Term Liabilities 102,59 220,85 5,10
Total Liabilities 274,29 324,64 77,52
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings -297,78 -211,44 -112,27 -177,32 -63,94 -100,11
Treasury Stock
Total Stockholder Equity 1 214,25 1 011,98 758,70 365,00 206,14 167,14
Net Tangible Assets 1 210,62 1 009,49 757,68 363,45 204,12 120,07